infinity pharmaceuticals inc (INFI) Key Developments
Infinity Pharmaceuticals, Inc. Enters into a First Amendment to Facility Agreement with Deerfield Management Company, L.P
Sep 26 14
Infinity Pharmaceuticals, Inc. entered into a first amendment to facility agreement with affiliates of Deerfield Management Company, L.P. to amend that certain facility agreement dated as of February 24, 2014 by and among the company and the lenders. Under the first amendment, the company and the lenders have agreed to reduce the maximum principal amount that the company may draw down under the credit facility established under the facility agreement, subject to the terms and conditions set forth therein, from $100,000,000 to $50,000,000. Accordingly, under the first amendment, the fee owed by the company on February 27, 2015 or upon the earlier termination or acceleration of the credit facility has been reduced from 3% of the then-undrawn portion of the previous $100,000,000 commitment to 3% of the then-undrawn portion of the revised $50,000,000 commitment. To date, the company has not drawn down any portion of funds available to it under the credit facility.
AbbVie Inc., Infinity Pharmaceuticals, Inc. - Special Call
Sep 3 14
To discuss the Infinity Pharmaceuticals, Inc.'s strategic collaboration with AbbVie Inc
Infinity Pharmaceuticals, Inc. and AbbVie Inc. Announce Global Strategic Collaboration to Develop and Commercialize duvelisib (IPI-145) in Oncology
Sep 3 14
Infinity Pharmaceuticals, Inc. and AbbVie Inc. announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). Infinity is conducting registration-focused trials evaluating the safety and efficacy of duvelisib, including DYNAMO(TM), a Phase 2 study in patients with iNHL, and DUO(TM), a Phase 3 study in patients with CLL. Under the terms of the agreement, Infinity will receive an upfront payment of $275 million and is eligible to receive up to $530 million in additional payments for the achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib. In the U.S., the companies will jointly commercialize duvelisib and will share equally in any potential profits. Outside the U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered double-digit royalties on net product sales. As part of the strategic collaboration, the companies will share responsibility for the conduct of specific trials specified within an agreed-upon global development plan, with each company leading the development of certain trials within the plan. The agreement includes plans to launch multiple Phase 2 and Phase 3 studies of duvelisib in hematologic malignancies over the next several years.
Infinity Pharmaceuticals, Inc. Enters into Master Clinical Supply Agreement and Material Transfer Agreement with Roche
Sep 3 14
Infinity Pharmaceuticals, Inc. announced that it has entered into a master clinical supply agreement with Roche under which Roche will supply Gazyva(TM) (obinutuzumab) to Infinity for use in planned clinical studies to evaluate the combination of Gazyva and duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with hematologic malignancies, or blood cancers. The companies have also entered into a material transfer agreement under which Infinity is supplying Roche with duvelisib for use in Roche's preclinical and translational research to evaluate the combination of duvelisib and Gazyva.
Infinity Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 11:40 AM
Aug 27 14
Infinity Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 11:40 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.